Birmingham-based contract research organization DiscoveryBioMed has been acquired by a company that provides drug discovery services and products.
Eurofins Discovery said in a release it acquired the growing local company for its expertise and experience supporting clients throughout the research process.
DiscoveryBioMed is focused on developing novel human bioassays using cells from diseased and normal human tissues. Bioassays determine the strength of a substance by comparing its effects on a test organism with those of a standard preparation.
DiscoveryBioMed achieves this through its focus on cellular models for the renal, skin, taste, ophthalmic, liver, respiratory, oncology and other therapeutic areas. It aims to fill a niche within the drug discovery industry by specializing in custom human cell engineering and human cell-based drug discovery and commercialization.
The addition of DiscoveryBioMed supports Eurofins Discovery's to have a complete portfolio of drug discovery services and products and strengthens its ability to support translational biology for drug discovery research and development.
With 58,000 staff across a network of 900 laboratories in 54 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.
